Linagliptin

Kimyoviy nomi:

8-[(3R)-3-aminopiperidin-1-il]-7-(but-2-in-1-il)-3- metil-1-[(4-metilkinazolin-2-il) metil]-3 ,7-dihidro-1H-purin-2,6-dion

SMILE kodi:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O

InChi kodi:

InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9, 12-15,26H2,1-3H3/t17-/m1/s1

InChi kaliti:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Kalit so'z:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Eruvchanligi:DMSOda eriydi

Saqlash:Qisqa muddatli (kunlardan haftalargacha) 0 - 4 ° C yoki uzoq muddatli (oylar) uchun -20 ° C.

Tavsif:

Linagliptin, shuningdek, BI-1356 sifatida ham tanilgan, II turdagi diabetni davolash uchun Boehringer Ingelheim tomonidan ishlab chiqilgan DPP-4 inhibitori. Linagliptin (kuniga bir marta) AQSh FDA tomonidan 2011 yil 2 mayda II turdagi diabetni davolash uchun tasdiqlangan. U Boehringer Ingelheim va Lilly tomonidan sotilmoqda.

Maqsad: DPP-4